DOCSLIB.ORG

EDCTP Portfolio Clinical Trials and Integrated Projects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EDCTP Portfolio Clinical Trials and Integrated Projects EDCTP Portfolio Clinical Trials and Integrated Projects The EDCTP portfolio of funded projects on HIV/AIDS covers drugs, vaccines and microbicides as well as capacity building projects that do not involve testing of investigational products. 1.1 HIV/AIDS treatment clinical trials ........................................................................... - 3 - 1.1.1 CHAPAS-1 ........................................................................................................... - 6 - 1.1.2 CHAPAS-3 .......................................................................................................... - 10 - 1.1.3 MONOD ............................................................................................................. - 15 - 1.1.4 EARNEST ........................................................................................................... - 18 - 1.1.5 2LADY ............................................................................................................... - 22 - 1.1.6 NUSTART ........................................................................................................... - 25 - 1.1.7 PROMPT ............................................................................................................. - 28 - 1.1.8 RAFA ................................................................................................................. - 31 - 1.1.9 REMSTART ......................................................................................................... - 34 - 1.2 HIV/AIDS prevention and treatment clinical trials .................................................... - 36 - 1.2.1 Kesho Bora study ................................................................................................ - 37 - 1.2.2 ComTru Study .................................................................................................... - 42 - 1.2.3 VITA Studies ...................................................................................................... - 46 - 1.2.4 PROMISE-PEP Studies .......................................................................................... - 51 - 1.3 HIV/AIDS microbicides capacity building and clinical trials ........................................ - 55 - 1.3.1 Van de Wijgert .................................................................................................... - 57 - 1.3.2 TVMTU ............................................................................................................... - 61 - 1.3.3 MRC CTU/MDP 301 .............................................................................................. - 66 - 1.3.4 Mandaliya-Biomarkers HIV Mic .............................................................................. - 72 - 1.4 HIV/AIDS vaccines capacity building ...................................................................... - 75 - 1.4.1 SASHA ............................................................................................................... - 77 - 1.4.2 HIVTAB .............................................................................................................. - 81 - 1.4.3 TaMoVac-01 ....................................................................................................... - 85 - 1.4.4 CHIVTUM ........................................................................................................... - 87 - 1.4.5 AfrEVacc ............................................................................................................ - 93 - 1.5 HIV/AIDS vaccines clinical trials .......................................................................... - 102 - 1.5.1 PedVacc ........................................................................................................... - 104 - 1.5.2 TaMoVac-01 ..................................................................................................... - 108 - 1.5.3 TaMoVac II ....................................................................................................... - 113 - 2 Tuberculosis ................................................................................................... - 116 - 2.1 Tuberculosis treatment clinical trials .................................................................... - 116 - 2.1.1 TB SurMark ...................................................................................................... - 118 - 2.1.2 HIV-TB Pharmagene .......................................................................................... - 121 - 2.1.3 PPK.DDK - HIV and TB medications ..................................................................... - 126 - 2.1.4 Rifaquin ........................................................................................................... - 130 - 2.1.5 REMox I and II ................................................................................................. - 132 - 2.1.6 PanACEA-HIGHRIF ............................................................................................ - 137 - 2.1.7 PanACEA-SQ109 ............................................................................................... - 142 - 2.2 Tuberculosis vaccines clinical trials ...................................................................... - 145 - 2.2.1 TB Vac prep Ethiopia/THYB-03 ............................................................................ - 146 - 2.2.2 Van't Hoog-TB Vac prep Kenya ........................................................................... - 149 - 2.2.3 TB Vac prep Uganda .......................................................................................... - 153 - 2.2.4 THYB-04 .......................................................................................................... - 156 - 2.2.5 TB-021 ............................................................................................................ - 160 - 2.2.6 AERAS 402/Crucell Ad35 .................................................................................... - 163 - 2.2.7 Aurum 102/THYB-05 ......................................................................................... - 167 - 2.3 Tuberculosis diagnostics clinical trials .................................................................. - 171 - 2.3.1 TB NEAT .......................................................................................................... - 173 - 2.3.2 TB CHILD ......................................................................................................... - 181 - 2.3.3 AE TBC ............................................................................................................ - 185 - 3 Malaria .......................................................................................................... - 189 - 3.1 Malaria treatment clinical trials ........................................................................... - 189 - 3.1.1 4ABC study ...................................................................................................... - 191 - 3.1.2 SMAC-II and III (Dose Optimisation Study) .......................................................... - 196 - 3.1.3 PREGACT ......................................................................................................... - 201 - 3.1.4 MiPPAD ............................................................................................................ - 208 - 3.1.5 IPTp-SP ........................................................................................................... - 215 - 3.1.6 WANECAM ........................................................................................................ - 223 - 3.1.7 ADAPT ............................................................................................................. - 230 - 3.2 Malaria vaccines clinical trials ............................................................................. - 235 - 3.2.1 GMZ2 .............................................................................................................. - 238 - 3.2.2 MVVC .............................................................................................................. - 241 - - 2 - 1.1 HIV/AIDS treatment clinical trials Project Phase Product(s) Manufacturer / Study population Status Acronym of trial Developer (Coordinator) CHAPAS-1 I/II Pedimune (Triomune Baby/Junior) Cipla PAEDIATRIC Completed (Chintu) tablets: Pharmaceuticals 211 HIV-1 infected children stavudine (d4T), lamivudine (3TC) (≥3 months - ≤14 years) and nevirapine (NVP) in paediatric co-formulated fixed-dose combinations CHAPAS-3 II Baby and Junior Triomune Cipla PAEDIATRIC Ongoing (Mulenga) (d4T+3TC+NVP); Lamivir S Pharmaceuticals Across the full paediatric age-range, in (d4T+3TC); both previously untreated (ART naïve) 3TC (lamivudine) +ABC (abacavir) children and in children with undetectable baby and junior scored tablets viral load who have already been ZDV (zidovudine) +3TC receiving d4T+3TC+NVP as first-line (lamivudine) baby and junior ART. scored tablets ZDV (zidovudine) +3TC 480 children aged 1 month to 13 years (lamivudine) +NVP (nevirapine) have been recruited from three Ugandan scored tablets. and one Zambian paediatric clinical centres and are followed for a minimum of 96 weeks. MONOD III Azidothymidine-Zidovudine (AZT); National PAEDIATRIC Ongoing (Leroy) Zidovudine (ZDV) syrup; programmes HIV-infected children (3 months – 12 Lamivudine (3TC) syrup; months) Nevirapine (NVP) syrup; Abacavir Early diagnosed between age 6 weeks (ABC) syrup ; Efavirenz (EFV) and 24 months of life syrup Initial prospective
Load more

Recommended publications
  • Persistence of Traditional and Emergence of New Structural Drivers and Factors for the HIV Epidemic in Rural Uganda; a Qualitative Study
    RESEARCH ARTICLE Persistence of traditional and emergence of new structural drivers and factors for the HIV epidemic in rural Uganda; A qualitative study 1 2 2 2 Francis BajunirweID *, Denis Akakimpa , Flora P. Tumwebaze , George Abongomera , Peter N. Mugyenyi2, Cissy M. Kityo2 1 Department of Community Health, Mbarara University of Science and Technology, Mbarara, Uganda, 2 Joint Clinical Research Center, Kampala, Uganda a1111111111 * [email protected] a1111111111 a1111111111 a1111111111 Abstract a1111111111 Background In Uganda, the HIV epidemic is now mature and generalized. Recently, there have been OPEN ACCESS reports of resurgence in the incidence of HIV after several years of successful control. The Citation: Bajunirwe F, Akakimpa D, Tumwebaze FP, causes for this resurgence are not clear but suspected to be driven by structural factors that Abongomera G, Mugyenyi PN, Kityo CM (2019) Persistence of traditional and emergence of new influence large groups of people rather than individuals. The aim of this study was to structural drivers and factors for the HIV epidemic describe the structural drivers of the HIV epidemic in high prevalence regions and inform the in rural Uganda; A qualitative study. PLoS ONE 14 next generation of interventions. (11): e0211084. https://doi.org/10.1371/journal. pone.0211084 Editor: Jerome T. Galea, University of South Methodology Florida, UNITED STATES We conducted a total of 35 focus group discussions in 11 districts in Uganda. Due to their Received: January 25, 2019 high HIV prevalence, the districts had been selected to implement a donor supported pro- Accepted: October 21, 2019 gram to scale up HIV prevention, care and treatment.
    [Show full text]
  • Proposal for Assessment of New Health Technologies
    v4.0 11.12.2017 Proposal for assessment of new health technologies Important information – read this first! Submitted proposals for national health technologies (HTAs) will be published in full. If the proposer thinks there is information necessary for filling out the form, that should not be made public, please contact the secretariat (Nye Metoder) before submission. The proposer is aware that the form will be published in its entirety (tick): ☒ Proposer has filled out point 19 below «Interests and, if any, conflicts of interest» (tick): ☒ This form serves the purpose to submit proposals for health technology assessment (HTA) at the national level in Nye Metoder - the national system for managed introduction of new health technologies within the specialist health service in Norway. The form does not apply to proposals for research projects. A health technology assessment is a type of evidence review, and for this to be possible, documentation is required, e.g. from completed clinical trials. Lack of documentation may be one of the reasons why the Commissioning Forum (Bestillerforum RHF) does not assign a health technology assessment. If the proposal concerns a medical device, the proposer is familiar with the document «Guidance criteria for management of medical devices in the National System for Managed Introduction of New Health Technologies within the Specialist Health Service in Norway» (link) (tick): ☒ Contact information: Name of the proposer (organization / institution / company / manufacturer): ViroGates A/S, Denmark Name of proposal contact: Jesper Eugen-Olsen, PhD Telephone number: +45 51 51 80 51 E-mail address: [email protected] Date and locality: 03-01-2019, Copenhagen Side 1 av 9 v4.0 11.12.2017 1.
    [Show full text]
  • Virogates Has Been Granted a New Patent to Measure the Risk of Developing Life Style Related Diseases Using Its Suparnostic ® Biomarker Product
    ViroGates has been granted a new patent to measure the risk of developing life style related diseases using its suPARnostic ® biomarker product Denmark, August 22, 2011 ViroGates, that develops and distributes the biomarker suPARnostic ®, today announced that it has been granted a patent in the UK, patent number GB2461410, based on the international patent application PCT/EP2007/064497. The patent is entitled “Method and tool for predicting cancer and other diseases”. The patent grant is the first related to the international patent application, and will allow ViroGates to pursue measuring and monitoring of patients’ blood, to determine whether the individual is at risk of developing life style related diseases such as cardiovascular diseases, type-2 diabetes (T2D), COPD and cancer. The grant of this patent further strengthens ViroGates’ patent portfolio, which comprises patents related to measuring and monitoring of various infectious diseases such as HIV, tuberculosis and various conditions of sepsis. The MONICA10 study (published in the Journal of Internal Medicine, 28 May 2010 by Jesper Eugen-Olsen, Ove Andersen and Steen B. Haugaard, Hvidovre University Hospital) has been the scientific basis for establishing this relation between suPAR and life style related diseases. The study documented that suPAR was predictive of development of cardiovascular diseases, diabetes and cancer, and particularly in predicting which individuals would progress to develop lung cancer. ViroGates, supported by a network of international key opinion leaders, is working towards establishing suPARnostic ® as a clinical decision-making product worldwide. “We are very excited to receive the news of this first grant of a patent relating to predicting serious life style related diseases” comments Jakob Knudsen, CEO of ViroGates.
    [Show full text]
  • Novel Biomarkers in the Management of HPV-Positive & -Negative Oropharyngeal Carcinoma January 2016
    THE UNIVERSITY OF SHEFFIELD Novel Biomarkers in the Management of HPV-Positive & -Negative Oropharyngeal Carcinoma Thesis submitted to the University of Sheffield for the degree of Doctor of Philosophy Robert Bolt Department of Oral & Maxillofacial Pathology January 2016 Abstract Human Papillomavirus (HPV)-related oropharyngeal carcinoma is considered to be in the early stages of an epidemic1-12. A marked rise in the incidence of this sexually-transmissible cancer has captured the public interest, and much debate exists over both the prophylactic and therapeutic strategies currently employed to manage this healthcare priority. HPV-positive oropharyngeal carcinoma is associated with highly favourable oncological outcomes. Clinical attention over recent years has been paid to the potential de-escalation of therapy in order to account for the disease’s favourable prognosis, in addition to reducing therapeutic burden in a well-prognosticating, younger patient cohort, for which consequences of radical chemo-radiotherapy strategies may disproportionately impact on longer-term quality of life. Whilst optimising the management of the ever-increasing proportion of HPV-positive oropharyngeal carcinomas is desirable and highly justifiable, it appears the poorer prognosticating HPV-negative oropharyngeal carcinoma has at least in part become overlooked. Oropharyngeal carcinoma is unique in comparison to many other established HPV-related cancers inasmuch as a clear HPV-negative subset exists, to which established aetiological factors (tobacco smoking and alcohol consumption) strongly correlate. For most other HPV- related carcinomas, such as cervical, anal and penile, tumours classified as HPV-negative are either regarded as potentially-virus containing, or else cannot be correlated to a definitive aetiological agent. Comparison of HPV-positive and -negative oropharyngeal carcinoma therefore offers unprecedented insight into the biological significance of each aetiological agent, and how prognostication of each disease may relate to tumour behaviour at a molecular level.
    [Show full text]
  • A Debilitating Effects of Low Back Pain Among Healthcare Workers
    ISSN: 2574-1241 Volume 5- Issue 4: 2018 DOI: 10.26717/BJSTR.2018.07.001556 Aremu Abdulmujeeb Babatunde. Biomed J Sci & Tech Res Research Article Open Access Social Disruptions and Work-Related Absenteeism: A Debilitating Effects of Low Back Pain Among Healthcare Workers Aremu Abdulmujeeb Babatunde*1, Nwanna Uchechukwu Kevin2, Ilori Oluwole3, Afolabi Kamaldeen Kolawole4 and Salaam Mujeeb5 1Human Anatomy/Community Medicine Department, Habib Medical School, Faculty of Health Science-Islamic University, Uganda 2Public Health Department, Victoria University, Uganda 3Behavioural Science Department, Habib Medical School, Faculty of Health Science-Islamic University, Uganda 4Public Health Department: Cavendish University Uganda 5Department of Pathology, Habib Medical School, Faculty of Health Science-Islamic University, Uganda Received: July 26, 2018; Published: August 09, 2018 *Corresponding author: Aremu Abdulmujeeb Babatunde, Human Anatomy/Community Medicine Department, Habib Medical School, Faculty of Health Science-Islamic University, Uganda Abstract Introduction : Consequently low back pain to the government and other employers (Healthcare industry) include high cost of workers’ compensation insurance to be paid to injured workers, recruitment or training costs and lost time This study sought to address the objectives : To determine if there is significant relationship between people suffering from low back pain and work related absenteeism and to determine if there is significantDesign: Thisrelationship was a qualitative between peopleand quantitative suffering fromusing low questionnaire, back pain and interviews social disruptions. and focus groups discussion. Setting and Participant: This study comprises of all healthcare workers present in Kibuli Muslim Hospital, Kibuli-Uganda Methods: A cross-sectional survey was employed and a total number of 150 self-structured questionnaires were distributed among healthcare workers and this was used to determine the prevalence of low back pain and work-related absenteeism.
    [Show full text]
  • The Snakebite Programme in Agok
    ISSN 2309 - 4605 eISSN 2309 - 4613 Volume 13. 4. November 2020 www.southsudanmedicaljournal.com SSMJSouth Sudan Medical Journal The snakebite programme in Agok • Nurses usage of CPAP in Tanzania • Inguinodynia and inguinal hernia recurrence • Reporting of adverse drug reactions • Developing an offline digital library • Multiple uterine fibroids • Rare heterotopic pregnancy • Penetrating arrow in the face 127 Vol 13. No 4. November 2020 South Sudan Medical Journal SSMJ South Sudan Medical Journal ISSN 2309 - 4605 eISSN 2309-4613 Volume 13 4 November 2020 A Publication of the South Sudan Medical Journal Juba Teaching Hospital, P. O. Box 88, Juba, South Sudan Email: admin@southernsudanmedicaljournal Website: www.southsudanmedicaljournal.com EDITOR-IN-CHIEF ASSOCIATE EDITORS Dr Edward Eremugo Kenyi Dr Wani Gindala Mena South Sudan Medical Journal Department of Ophthalmology Juba, South Sudan Juba Teaching Hospital, PO Box 88, EDITORS Juba, South Sudan Prof John Adwok Prof James Gita Hakim Dr Eluzai Abe Hakim Dr Charles Bakhiet Retired Consultant Physician, St. Mary’s Hospital, Newport, Dr Charles Ochero Cornelio Isle of Wight, PO30 5TG, UK Dr Ayat C. Jervase International Adviser to the Royal College of Physicians Dr James Ayrton London on South Sudan Dr David Tibbutt EDITORIAL ASSISTANTS EDITORIAL ADVISOR Dr Nyakomi Adwok Ann Burgess Dr Grace Juan Soma Nancy MacKeith WEB TEAM Dr Edward Eremugo Kenyi DESIGN AND LAYOUT Rachel Ayrton Dr Edward Eremugo Kenyi Index and Copyright Information The South Sudan Medical Journal is a quarterly publication intended for Healthcare Professionals, both those working in the South Sudan and those in other parts of the world seeking information on health in South Sudan.
    [Show full text]
  • See Virogates Presentation Here
    ViroGates ViroGates A/S Västra Hamnen Investor Day 2 December 2020 ViroGates 2 ViroGates - a commercial stage company with approved products for the hospital sector ViroGates suPARnostic® products suPAR is the biomarker detected by ViroGates’ three CE-IVD marked suPARnostic® products and is a protein found in plasma. Description ViroGates A/S is an international medical technology ViroGates has established clinical utility of suPARnostic® supported by company developing and marketing blood test products +700 peer reviewed publications. under the suPARnostic® brand for better triaging in hospitals to: ViroGates has patented the clinical use of suPAR levels as a risk stratification method and currently holds 4 granted patent families and one newly filed application (2018). improve patient care reduce healthcare costs AUTO Flex ELISA Quick Triage TurbiLatex empower clinical staff Application R&D & clinical Near-patient Automated, use lab centralized lab ViroGates was founded in 2001 and has since 2018 been listed on Nasdaq First North Growth Market DK – Ticker Technology ELISA Lateral flow Turbidimetric “VIRO” Launch year 2009 2015 2018 (CE-IVD) ViroGates 3 suPAR is a marker of immune activation and a strong predictor disease severity and progession uPAR suPAR suPARnostic® +700 peer (soluble urokinase Plasminogen Activator Receptor) suPAR DI DI DII DII reviewed papers supporting A prognostic inflammatory DIII DIII evidence biomarker for immune activation indicating: Kidney disease Liver disease • Disease presence (acute, Diabetes Elevated
    [Show full text]
  • Malaria Journal
    Lwanira et al. Malar J (2017) 16:322 DOI 10.1186/s12936-017-1970-1 Malaria Journal RESEARCH Open Access Prevalence of polymorphisms in glucose‑6‑phosphate dehydrogenase, sickle haemoglobin and nitric oxide synthase genes and their relationship with incidence of uncomplicated malaria in Iganga, Uganda Catherine Nassozi Lwanira1†, Fred Kironde2*† , Mark Kaddumukasa3 and Göte Swedberg4 Abstract Background: Host genetics play an important role in Plasmodium falciparum malaria susceptibility. However, information on host genetic factors and their relationships with malaria in the vaccine trial site of Iganga, Uganda is limited. The main objective of this study was to determine the prevalence of selected host genetic markers and their relationship to malaria incidence in the vaccine trial site of Iganga, Uganda. In a 1-year longitudinal cohort study, 423 children aged below 9 years were recruited and their malaria episodes were investigated. Host genetic polymor- phisms were assessed by PCR–RFLP, haemoglobin electrophoresis and DNA sequencing. Using a multivariate negative binomial regression model, estimates of the impact of human genetic polymorphisms on malaria incidence were performed. In all statistical tests, a P value of <0.05 was considered as signifcant. Results: The prevalences of sickle cell haemoglobin trait, G6PD c.202 G>A (rs 1050828) and NOS2 954 G>C (rs 1800482) variants were 26.6, 22.7 and 17.3%, respectively. Inducible nitric oxide synthase 2 (NOS2 −954 G>C; rs 1800482) heterozygosity was associated with lower incidence of malaria in all age groups {Adjusted− incident rates ratio (aIRR) 0.59; 95% CI [0.386–0.887]; P 0.012)}.
    [Show full text]
  • Serena Hotel and Conference Centre Kampala, Uganda May 26–27, 2011 Table of Contents
    Program Serena Hotel and Conference Centre Kampala, Uganda MAY 26–27, 2011 Table of Contents Welcome Letter . 3 Acknowledgements . 4 General Information . 5 Agenda . 9 u Wednesday, May 25, 2011 . 9 u Thursday, May 26, 2011 . 9 u Friday, May 27, 2011 . .11 Conference Centre Floor Plan . 13 Abstracts . 14 Attendee List . 38 Attendee Collaboration Information . 47 SUB-SAHARAN AFRICA CFAR CONFERENCE 2011 1 Dear CFAR Colleagues and Partners! On behalf of the U .S . National Institutes of Health-sponsored Centers for AIDS Research, and Makerere University’s Infectious Diseases Institute, welcome to Kampala! It is our pleasure and honor to have you join us for the 2011 Sub-Saharan Africa CFAR Conference as we gather to feature some of the important research being conducted by African investigators collaborating with the 21 Centers for AIDS Research (CFARs) . Our Conference Steering Committee is planning an exciting program focusing on three priority themes: u Integrating Treatment and Prevention in HIV Care u HIV Comorbidities u HIV and Women Through a combination of plenary and poster presentations, panel discussions, and networking sessions, this meeting will present a unique opportunity for both scientific and information exchange . A special effort will be made to provide a platform for sharing information on existing scientific resources and infrastructure at leading African institutions that support AIDS research and training – a critical prerequisite for the exchange of scientific resources, capacity building, and the fostering of new collaborations among African institutions . The conference has already generated much energy and interest . We envision this momentum leading to the emergence of an African-led network that will build on existing collaborations and begin to explore potential synergies with new partners – including other CFARs, other complementary networks active in Africa, and in particular, South-South partnerships among African institutions – to strengthen the community of science on the continent .
    [Show full text]
  • Of Body Inflammation for Maxillofacial Surgery Purpose-To Make
    applied sciences Article Index of Body Inflammation for Maxillofacial Surgery Purpose-to Make the Soluble Urokinase-Type Plasminogen Activator Receptor Serum Level Independent on Patient Age Marcin Kozakiewicz 1,*, Magdalena Trzci´nska-Kubik 1 and Rafał Nikodem Wlazeł 2 1 Department of Maxillofacial Surgery, Medical University of Lodz, 113 Zeromskiego˙ Str., 90-549 Lodz, Poland; [email protected] 2 Department of Laboratory Diagnostics and Clinical Biochemistry, Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-42-6393068 Featured Application: Inflammation is still a threat to patients of all age groups. Monitoring the infection is essential to control it. The soluble urokinase-type plasminogen activator receptor (suPAR) is a very sensitive marker. Maxillofacial surgery is one of the fields of medicine widely fighting against infections. The concentration of suPAR holds an independent information for risk stratification of morbidity and mortality in various acute and chronic diseases. The use of an ultra-sensitive measure of the development of inflammation and at the same time independent on the patient’s age would be clinically very beneficial. Abstract: Background: The serum suPAR level is affected in humans by it increases with age. Therefore it makes difficult interpretation and any comparison of age varied groups. The aim of this Citation: Kozakiewicz, M.; study is to find simple way to age independent presentation of suPAR serum level for maxillofacial Trzci´nska-Kubik,M.; Wlazeł, R.N. surgery purpose. Methods: In generally healthy patients from 15 to 59 y.o. suPAR level was tested Index of Body Inflammation for in serum before orthognathic or minor traumatologic procedures.
    [Show full text]
  • Plasma Levels of the Active Form of Supar Are Associated with COVID
    Huang et al. Crit Care (2020) 24:704 https://doi.org/10.1186/s13054-020-03336-0 LETTER Open Access Plasma levels of the active form of suPAR are associated with COVID-19 severity Mingxiang Huang1†, Linlin Li2†, Jianshan Shen1, Yao Wang1, Rui Wang1, Cai Yuan3, Mingdong Huang2* and Longguang Jiang2,4* We read with great interest the recent study by Rovina not only signifcantly higher than those in healthy con- et al., who found that the elevation of soluble urokinase trols (p < 0.0001) but also slightly higher than those in plasminogen activator receptor (suPAR) plasma levels COVID-19 patients (p = 0.0278) (Table 1, Fig. 1a). Even in coronavirus disease 2019 (COVID-19) patients, and though more data needs to be collected and the back- suggested the suPAR can be an early predictor of severe ground of these patients are not clear, this is a signifcant respiratory failure [1]. Tere are three diferent suPAR research direction to pursue. If asymptomatic carriers forms (suPAR DI-III, suPAR DI, and suPAR DII-III) in could be identifed and quarantined in an early stage, it circulation, in which suPAR DI-III is defned as the active will prevent them from increasing the disease transmis- form of suPAR by its capability of binding to uPA [2]. In sion to an uncontrollable manner. addition, the uPA/uPAR system as a therapeutic target Patients involved three types of symptoms: moderate, has been proposed to reduce mortality of COVID-19 [3]; severe, and critical in our study (Table 1). Our data show therefore, further evaluation of the active form of suPAR that active suPAR levels increase as the disease worsens plasma levels in diferent symptom types of COVID-19 (Fig.
    [Show full text]
  • Virogates A/S Investor Presentation 16 June 2020 Danske Bank, Copenhagen Virogates
    ViroGates ViroGates A/S Investor Presentation 16 June 2020 Danske Bank, Copenhagen ViroGates Forward-looking statements Certain information set forth and given in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of ViroGates A/S (ViroGates); (ii) the expected development of ViroGates’ business, projects and joint ventures; (iii) execution of ViroGates’ vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for ViroGates’ projects; (v) completion of ViroGates’ projects that are currently underway, in development or otherwise under consideration; (vi) renewal of ViroGates’ current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward- looking statements necessarily
    [Show full text]